Biocytogen/Eucure Biopharma's YH001 (Anti-CTLA-4 M...

BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogendedicated to developing proprietary antibody drugs,announced that the China National Medical Products Administration (NMPA) has approved YH001 for phase II Multi-R...

Biocytogen/Eucure Biopharma's YH003 (Anti-CD40 Mon...

BEIJING, November 2, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogendedicated to developing proprietary antibody drugs,announced that the China National Medical Products Administration (NMPA) has approved YH003 for phase II Multi...

Eucure Biopharma, a Subsidiary of Biocytogen, and...

YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials sponsored by Eucure Biopharma in Australia and China TRACON intends to...

Eucure Biopharma to Present Clinical Data Presenta...

BEIJING, September 25-29, 2021 — The 24th National Conference on clinical oncology and the 2021 CSCO annual conference will be held online and offline in the form of seminar and MDT discussion. The theme of this conference is "focus on innovative res...

Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs...

BOSTON and BEIJING, June 29, 2021 –Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced that the U.S. Food and Drug Administration (FDA) has approved...

Eucure Biopharma to Present Findings From Anti-CD4...

BEIJINGandBOSTON,June 1, 2021/PRNewswire/ — Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held fromJune 4thto 8th. The first trial (poster #2580...